Pharmacometabolomics in Drug Mechanism, Efficacy and Toxicity
A Special Issue of Metabolites (ISSN 2218-1989) belonging to the section "Pharmacology and Drug Metabolism".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 1054
Editors
2 INBB—Biostructures and Biosystems National Institute, 00136 Roma, Italy
Interests: endocrine disruptors toxicity and mode of action; probiotic as mitigation strategy; metabolomics; proteomics; transcript analysis; histology and immunohistochemistry; cell culture; 3D in vitro models; organoids; spheroids
Interests: bioactive compounds; oxidative stress; inflammation; human nutrition; lipoproteins; paraoxonase 2
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pharmacometabolomics is rapidly emerging as a powerful systems-level approach to elucidate how drugs interact with the complexity of human metabolism. By integrating advanced metabolite profiling, computational analytics and mechanistic interpretation, pharmacometabolomics offers unprecedented opportunities to characterize drug actions, predict therapeutic responses and identify pathways underlying adverse effects. This Special Issue, Pharmacometabolomics in Drug Mechanism, Efficacy and Toxicity, aims to gather cutting-edge contributions that advance our understanding of how metabolic networks shape and are shaped by pharmacological interventions.
The focus of this Special Issue is to highlight methodological and conceptual innovations that leverage metabolomics, lipidomics, cheminformatics, metabolic flux analysis and computational modelling to unravel drug‐related biochemical processes. Studies exploring novel workflows for biological sample preparation, improvements in low-molecular-weight metabolite detection and curation and integrated multi-omics approaches are particularly welcome.
The scope encompasses experimental, translational and computational research across diverse biological systems, from cell models to animal models and human studies. We invite submissions addressing metabolic signatures of drug efficacy, resistance and toxicity; downstream metabolic consequences of genetic or environmental perturbations; and biomarker discovery for personalized medicine. Contributions that demonstrate the clinical and industrial relevance of pharmacometabolomics, including applications in toxicology, metabolic disease and environmental exposure assessment, are also encouraged.
The purpose of this Special Issue is to provide a comprehensive platform for researchers working at the interface of metabolism and pharmacology, promoting novel insights into metabolic pathways that define drug behavior. By consolidating emerging trends and innovative approaches, this issue aims to foster progress toward more effective, safer and personalized therapeutic strategies.
Dr. Christian Giommi
Dr. Camilla Morresi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacometabolomics
- drug mechanisms
- metabolic biomarkers
- drug efficacy
- drug toxicity
- metabolic flux analysis
- lipidomics and metabolomics profiling
- computational metabolomics
- systems pharmacology
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
